Formulation And Evaluation Of Mucoadhesive Buccal Tablet Of Favipiravir

This research work investigates the formulation and evaluation of mucoadhesive buccal tablets containing Favipiravir, an antiviral medication with proven efficacy against various RNA viruses, including influenza and certain strains of coronaviruses. The objective of this study is to develop a novel drug delivery system that enhances the bioavailability and therapeutic efficacy of Favipiravir through buccal administration, thereby addressing the limitations associated with conventional oral dosage forms. The formulation development phase involves the selection of suitable mucoadhesive polymers such as Carbopol 934, sodium carboxy methyl cellulose and other excipients to optimize the mechanical properties, drug release kinetics, and adhesive characteristics of the buccal tablets. The mucoadhesive buccal tablet of Favipiravir was formulated by using direct compression method by using different polymer. The developed formulations may offer advantages such as improved patient compliance, reduced systemic side effects, and rapid onset of action, making them promising candidates for the treatment of respiratory viral infections and other diseases requiring localized drug delivery via the buccal route.